Renato D Lopes1, Hwanhee Hong2,3, Ralf E Harskamp4, Deepak L Bhatt5, Roxana Mehran6,7, Christopher P Cannon5, Christopher B Granger1, Freek W A Verheugt8, Jianghao Li1, Jurriën M Ten Berg9,10, Nikolaus Sarafoff11, Pascal Vranckx12, Andreas Goette13, C Michael Gibson14, John H Alexander1. 1. Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. 3. Department of Biostatistics and Bioinformatics, Duke University of School of Medicine, Durham, North Carolina. 4. Amsterdam UMC-University of Amsterdam, Academic Medical Center, Amsterdam, the Netherlands. 5. Heart & Vascular Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 6. The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York. 7. Associate Editor. 8. Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands. 9. Department of Cardiology and Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands. 10. Department of Cardiology, Universitair Medisch Centrum Groningen, Groningen, the Netherlands. 11. Deutsches Herzzentrum Munchen, Klinik fur Herz-und Kreislauferkrankungen, Ludwig-Maximilians-Universität München, Munich, Germany. 12. Department of Cardiology and Intensive Care, Jessa Ziekenhuis, Faculty of Medicine and Life Sciences at the Hasselt University, Hasselt, Belgium. 13. Cardiology and Intensive Care Medicine, St Vincenz-Hospital, Paderborn, Germany. 14. Cardiovascular Division, Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
Importance: Antithrombotic treatment in patients with atrial fibrillation (AF) and percutaneous coronary intervention (PCI) presents a balancing act with regard to bleeding and ischemic risks. Objectives: To evaluate the safety and efficacy of 4 antithrombotic regimens by conducting an up-to-date network meta-analysis and to identify the optimal treatment for patients with AF undergoing PCI. Data Sources: Online computerized database (MEDLINE). Study Selection: Five randomized studies were included (N = 11 542; WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI). Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used in this network meta-analysis, in which bayesian random-effects models were applied. The data were analyzed from September 9 to 29, 2019. Main Outcomes and Measures: The primary safety outcome was thrombolysis in myocardial infarction (TIMI) major bleeding and the primary efficacy outcome was trial-defined major adverse cardiovascular events (MACE). Results: The total number of participants included in the study was 11 532. The mean age of the participants ranged from 70 to 72 years, 69% to 83% were male, 20% to 26% were female, and the participants were predominantly white (>90%). Compared with vitamin K antagonists (VKA) plus dual antiplatelet therapy (DAPT) (reference), the odds ratios (ORs) (95% credible intervals) for TIMI major bleeding were 0.57 (0.31-1.00) for VKA plus P2Y12 inhibitor, 0.69 (0.40-1.16) for non-VKA oral anticoagulant (NOAC) plus DAPT, and 0.52 (0.35-0.79) for NOAC plus P2Y12 inhibitor. For MACE, using VKA plus DAPT as reference, the ORs (95% credible intervals) were 0.97 (0.64-1.42) for VKA plus P2Y12 inhibitor, 0.95 (0.64-1.39) for NOAC plus DAPT, and 1.03 (0.77-1.38) for NOAC plus P2Y12 inhibitor. Conclusions and Relevance: The findings of this study suggest that an antithrombotic regimen of VKA plus DAPT should generally be avoided, because regimens in which aspirin is discontinued may lead to lower bleeding risk and no difference in antithrombotic effectiveness. The use of a NOAC plus a P2Y12 inhibitor without aspirin may be the most favorable treatment option and the preferred antithrombotic regimen for most patients with AF undergoing PCI.
Importance: Antithrombotic treatment in patients with atrial fibrillation (AF) and percutaneous coronary intervention (PCI) presents a balancing act with regard to bleeding and ischemic risks. Objectives: To evaluate the safety and efficacy of 4 antithrombotic regimens by conducting an up-to-date network meta-analysis and to identify the optimal treatment for patients with AF undergoing PCI. Data Sources: Online computerized database (MEDLINE). Study Selection: Five randomized studies were included (N = 11 542; WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI). Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used in this network meta-analysis, in which bayesian random-effects models were applied. The data were analyzed from September 9 to 29, 2019. Main Outcomes and Measures: The primary safety outcome was thrombolysis in myocardial infarction (TIMI) major bleeding and the primary efficacy outcome was trial-defined major adverse cardiovascular events (MACE). Results: The total number of participants included in the study was 11 532. The mean age of the participants ranged from 70 to 72 years, 69% to 83% were male, 20% to 26% were female, and the participants were predominantly white (>90%). Compared with vitamin K antagonists (VKA) plus dual antiplatelet therapy (DAPT) (reference), the odds ratios (ORs) (95% credible intervals) for TIMI major bleeding were 0.57 (0.31-1.00) for VKA plus P2Y12 inhibitor, 0.69 (0.40-1.16) for non-VKA oral anticoagulant (NOAC) plus DAPT, and 0.52 (0.35-0.79) for NOAC plus P2Y12 inhibitor. For MACE, using VKA plus DAPT as reference, the ORs (95% credible intervals) were 0.97 (0.64-1.42) for VKA plus P2Y12 inhibitor, 0.95 (0.64-1.39) for NOAC plus DAPT, and 1.03 (0.77-1.38) for NOAC plus P2Y12 inhibitor. Conclusions and Relevance: The findings of this study suggest that an antithrombotic regimen of VKA plus DAPT should generally be avoided, because regimens in which aspirin is discontinued may lead to lower bleeding risk and no difference in antithrombotic effectiveness. The use of a NOAC plus a P2Y12 inhibitor without aspirin may be the most favorable treatment option and the preferred antithrombotic regimen for most patients with AF undergoing PCI.
Authors: Renato D Lopes; Gretchen Heizer; Ronald Aronson; Amit N Vora; Tyler Massaro; Roxana Mehran; Shaun G Goodman; Stephan Windecker; Harald Darius; Jia Li; Oleg Averkov; M Cecilia Bahit; Otavio Berwanger; Andrzej Budaj; Ziad Hijazi; Alexander Parkhomenko; Peter Sinnaeve; Robert F Storey; Holger Thiele; Dragos Vinereanu; Christopher B Granger; John H Alexander Journal: N Engl J Med Date: 2019-03-17 Impact factor: 91.245
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Eugenia Nikolsky; Roxana Mehran; George D Dangas; Jennifer Yu; Helen Parise; Ke Xu; Stuart J Pocock; Gregg W Stone Journal: Am J Cardiol Date: 2011-12-22 Impact factor: 2.778
Authors: Renato D Lopes; Hwanhee Hong; Ralf E Harskamp; Deepak L Bhatt; Roxana Mehran; Christopher P Cannon; Christopher B Granger; Freek W A Verheugt; Jianghao Li; Jurriën M Ten Berg; Nikolaus Sarafoff; C Michael Gibson; John H Alexander Journal: JAMA Cardiol Date: 2019-08-01 Impact factor: 14.676
Authors: J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook Journal: Circulation Date: 1987-07 Impact factor: 29.690
Authors: Pascal Vranckx; Marco Valgimigli; Lars Eckardt; Jan Tijssen; Thorsten Lewalter; Giuseppe Gargiulo; Valerii Batushkin; Gianluca Campo; Zoreslava Lysak; Igor Vakaliuk; Krzysztof Milewski; Petra Laeis; Paul-Egbert Reimitz; Rüdiger Smolnik; Wolfgang Zierhut; Andreas Goette Journal: Lancet Date: 2019-09-03 Impact factor: 79.321
Authors: Morten Lamberts; Jonas Bjerring Olesen; Martin Huth Ruwald; Carolina Malta Hansen; Deniz Karasoy; Søren Lund Kristensen; Lars Køber; Christian Torp-Pedersen; Gunnar Hilmar Gislason; Morten Lock Hansen Journal: Circulation Date: 2012-08-06 Impact factor: 29.690
Authors: M Cecilia Bahit; Amit N Vora; Zhuokai Li; Daniel M Wojdyla; Laine Thomas; Shaun G Goodman; Ronald Aronson; J Dedrick Jordan; Brad J Kolls; Keith E Dombrowski; Dragos Vinereanu; Sigrun Halvorsen; Otavio Berwanger; Stephan Windecker; Roxana Mehran; Christopher B Granger; John H Alexander; Renato D Lopes Journal: JAMA Cardiol Date: 2022-07-01 Impact factor: 30.154
Authors: Ali Coner; Cenk Ekmekci; Gokhan Aydin; Yasemin Kilavuz Dogan; Ozlem Arican Ozluk; Salih Kilic; Yunus Celik; Ismail Ungan; Mustafa Begenc Tascanov; Ramazan Duz; Veli Polat; Hakan Ozkan; Mehmet Ozyasar; Kamil Tuluce; Abdullah Icli; Devrim Kurt; Nurullah Cetin; Murat Gul; Sinan Inci; Mehdi Zoghi; Oktay Ergene; Ugur Onsel Turk Journal: J Atr Fibrillation Date: 2021-04-30
Authors: José Carlos Nicolau; Gilson Soares Feitosa Filho; João Luiz Petriz; Remo Holanda de Mendonça Furtado; Dalton Bertolim Précoma; Walmor Lemke; Renato Delascio Lopes; Ari Timerman; José A Marin Neto; Luiz Bezerra Neto; Bruno Ferraz de Oliveira Gomes; Eduardo Cavalcanti Lapa Santos; Leopoldo Soares Piegas; Alexandre de Matos Soeiro; Alexandre Jorge de Andrade Negri; Andre Franci; Brivaldo Markman Filho; Bruno Mendonça Baccaro; Carlos Eduardo Lucena Montenegro; Carlos Eduardo Rochitte; Carlos José Dornas Gonçalves Barbosa; Cláudio Marcelo Bittencourt das Virgens; Edson Stefanini; Euler Roberto Fernandes Manenti; Felipe Gallego Lima; Francisco das Chagas Monteiro Júnior; Harry Correa Filho; Henrique Patrus Mundim Pena; Ibraim Masciarelli Francisco Pinto; João Luiz de Alencar Araripe Falcão; Joberto Pinheiro Sena; José Maria Peixoto; Juliana Ascenção de Souza; Leonardo Sara da Silva; Lilia Nigro Maia; Louis Nakayama Ohe; Luciano Moreira Baracioli; Luís Alberto de Oliveira Dallan; Luis Augusto Palma Dallan; Luiz Alberto Piva E Mattos; Luiz Carlos Bodanese; Luiz Eduardo Fonteles Ritt; Manoel Fernandes Canesin; Marcelo Bueno da Silva Rivas; Marcelo Franken; Marcos José Gomes Magalhães; Múcio Tavares de Oliveira Júnior; Nivaldo Menezes Filgueiras Filho; Oscar Pereira Dutra; Otávio Rizzi Coelho; Paulo Ernesto Leães; Paulo Roberto Ferreira Rossi; Paulo Rogério Soares; Pedro Alves Lemos Neto; Pedro Silvio Farsky; Rafael Rebêlo C Cavalcanti; Renato Jorge Alves; Renato Abdala Karam Kalil; Roberto Esporcatte; Roberto Luiz Marino; Roberto Rocha Corrêa Veiga Giraldez; Romeu Sérgio Meneghelo; Ronaldo de Souza Leão Lima; Rui Fernando Ramos; Sandra Nivea Dos Reis Saraiva Falcão; Talia Falcão Dalçóquio; Viviana de Mello Guzzo Lemke; William Azem Chalela; Wilson Mathias Júnior Journal: Arq Bras Cardiol Date: 2021-07 Impact factor: 2.667
Authors: Leonardo De Luca; Raffaella Mistrulli; Francesco Antonio Veneziano; Francesco Grigioni; Massimo Volpe; Francesco Musumeci; Domenico Gabrielli Journal: J Clin Med Date: 2022-01-20 Impact factor: 4.241
Authors: Davide Capodanno; Marco Di Maio; Antonio Greco; Deepak L Bhatt; C Michael Gibson; Andreas Goette; Renato D Lopes; Roxana Mehran; Pascal Vranckx; Dominick J Angiolillo Journal: J Am Heart Assoc Date: 2020-08-01 Impact factor: 5.501
Authors: Giuseppe Gargiulo; Christopher P Cannon; Charles Michael Gibson; Andreas Goette; Renato D Lopes; Jonas Oldgren; Serge Korjian; Stephan Windecker; Giovanni Esposito; Pascal Vranckx; Marco Valgimigli Journal: Eur Heart J Cardiovasc Pharmacother Date: 2021-04-09